Historical Control Analysis Demonstrates Greater Long-Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease. - Germain DP; DasMahapatra P; Liu S; Deegan P; Ortiz A; Modur V; Wilcox WR (Molecular Genetics & Genomic Medicine, 2025)